The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province

• Conditions: Gastric Cancer

• Registration Number: NCT03333967
• Lead Sponsor: The First Affiliated Hospital of Anhui Medical University

Brief Summary

The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-09
• Study Start: 2017-09-01
• Study First Submitted: 2017-10-01
• Study First Submitted QC: 2017-11-06
• Last Update Submitted: 2017-11-06
• Study First Posted: 2017-11-07
• Last Update Posted: 2017-11-07
• Primary Completion: 2019-09-01
• Study Completion: 2020-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Male or female patients .
2. Confirmed by Pathology or histology of Gastric cancer
3. Patients should be voluntary to the trial and provide with signed informed consent
4. The researchers believe patients can benefit from the study.

Exclusion Criteria

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories
2. Pregnant or lactating women
3. Patients with Apatinib contraindications
4. Patients of doctors considered unsuitable for the trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progress free survival	1 year	Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.

Secondary Outcome Measures

Name	Time	Method
overall survival	3year	overall survival is defined as the length of time from random assignment to death or to last contact.
Objective tumor response rate	1year	Objective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments
disease control rate	1year	Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1
Disease-free survival	1 year	Disease-free survival is defined as the length of time from the date of randomization to the date of first documentation of relapse of gastric cancer or any other type of cancer or death.

Trial Locations

Locations (1)

First Affiliated Hospital of Anhui Medical University; 🇨🇳 Hefei, Anhui, China